TOPICAL BLOOD CLOTTING AGENTS

Brand Owner (click to sort) Address Description
SEPTI-STAT SOLUBLE PRODUCTS, CORP. 37 MERIDIAN ROAD EDISON NJ 08817 TOPICAL BLOOD CLOTTING AGENTS AND PROTECTIVE POROUS COVERS, DRESSINGS AND BANDAGES FOR CONTROLLING SUPERFICIAL BLEEDING AND FOR PROMOTING HEALING OF MINOR CUTS, BURNS AND ABRASIONS;SEPTI-STAT;SEPTIC-STAT;
THERA-SKIN SOLUBLE PRODUCTS CORP. 360 FURMAN ST. BROOKLYN NY TOPICAL BLOOD CLOTTING AGENTS AND PROTECTIVE POROUS COVERS, DRESSINGS AND BANDAGES FOR CONTROLLING SUPERFICIAL BLEEDING AND FOR PROMOTING HEALING OF MINOR CUTS, BURNS AND ABRASIONS, IN ALL MARKETS OTHER THAN THE OVER-THE-COUNTER RETAIL MARKET;
 

Where the owner name is not linked, that owner no longer owns the brand

   
Technical Examples
  1. The present invention relates to the isolation and identification of novel baboon nucleic acid molecules and proteins and polypeptides encoded by such nucleic acid molecules, or degenerate variants thereof, which proteins and polypeptides comprise novel baboon thrombin-activatable fibrinolysis inhibitors or "TAFI" enzyme molecules. Because the novel baboon TAFI proteins and polypeptides of the invention inhibit the breakdown of blood clots, they may be therapeutically useful for the treatment of blood disorders wherein clotting needs to be regulated or promoted, such as hemophilia or von Willebrand's disease or in other situations, such as trauma, wherein blood clotting or coagulation needs to be regulated or promoted. The sequences of the invention are also useful in screening methods for the identification of compounds that modulate the expression of the baboon TAFI nucleic acids and/or the activity of the baboon TAFI proteins and polypeptides of the invention. Such agonist or antagonist compounds may be useful in the treatment of various blood clotting disorders and conditions requiring hemostatic control such as hemophilia or various thrombotic diseases such as deep venous thrombosis, coronary artery disease, stroke associated with atrial fibrillation and recurrent thrombosis following stroke or myocardial infarction.